Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria

Trial Profile

Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Golimumab (Primary)
  • Indications Spondylarthritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CRESPA
  • Most Recent Events

    • 16 Jun 2018 Results of CRESPA-Extension protocol assessing the need for Anti-Tnf Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis (n=23) presented at the 19th Annual Congress of the European League Against Rheumatism
    • 08 Nov 2017 Results assessing patient characteristics predicting sustained remission or occurrence of relapse after drug withdrawal, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top